Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study

PURPOSE: Primary mediastinal B‐cell lymphoma (PMBCL) is a rare subtype of diffuse large B‐cell lymphoma (DLBCL). Despite its aggressive course, PMBCL is considered curable. While in recent years dose‐adjusted (DA) EPOCH‐R (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubic...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgenstern, Yael, Aumann, Shlomzion, Goldschmidt, Neta, Gatt, Moshe E., Nachmias, Boaz, Horowitz, Netanel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683525/
https://www.ncbi.nlm.nih.gov/pubmed/34816617
http://dx.doi.org/10.1002/cam4.4387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683525/
https://www.ncbi.nlm.nih.gov/pubmed/34816617
http://dx.doi.org/10.1002/cam4.4387

Ejemplares similares